WO2023084474A1 - 조절 t세포의 바이오 마커 - Google Patents
조절 t세포의 바이오 마커 Download PDFInfo
- Publication number
- WO2023084474A1 WO2023084474A1 PCT/IB2022/060908 IB2022060908W WO2023084474A1 WO 2023084474 A1 WO2023084474 A1 WO 2023084474A1 IB 2022060908 W IB2022060908 W IB 2022060908W WO 2023084474 A1 WO2023084474 A1 WO 2023084474A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- cells
- disease
- regulatory
- protein
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title claims abstract description 153
- 239000000090 biomarker Substances 0.000 title abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 162
- 238000000034 method Methods 0.000 claims description 113
- 102000004169 proteins and genes Human genes 0.000 claims description 88
- 206010028980 Neoplasm Diseases 0.000 claims description 83
- 210000004027 cell Anatomy 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 51
- 230000014509 gene expression Effects 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 36
- 239000012530 fluid Substances 0.000 claims description 36
- 238000004458 analytical method Methods 0.000 claims description 31
- 108010052285 Membrane Proteins Proteins 0.000 claims description 28
- 102000018697 Membrane Proteins Human genes 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 28
- 230000027455 binding Effects 0.000 claims description 25
- 238000010839 reverse transcription Methods 0.000 claims description 25
- 238000003745 diagnosis Methods 0.000 claims description 24
- 238000003556 assay Methods 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 17
- 238000003757 reverse transcription PCR Methods 0.000 claims description 16
- 102100027207 CD27 antigen Human genes 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 15
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 15
- 208000012902 Nervous system disease Diseases 0.000 claims description 15
- 102100021269 Regulator of G-protein signaling 1 Human genes 0.000 claims description 15
- 101710140408 Regulator of G-protein signaling 1 Proteins 0.000 claims description 15
- 210000000056 organ Anatomy 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 14
- 239000012472 biological sample Substances 0.000 claims description 14
- 210000000265 leukocyte Anatomy 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 13
- 238000000636 Northern blotting Methods 0.000 claims description 12
- 108010083644 Ribonucleases Proteins 0.000 claims description 12
- 102000006382 Ribonucleases Human genes 0.000 claims description 12
- 230000002860 competitive effect Effects 0.000 claims description 12
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 11
- 230000004770 neurodegeneration Effects 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 208000006673 asthma Diseases 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- 210000004880 lymph fluid Anatomy 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
- 210000001138 tear Anatomy 0.000 claims description 10
- 238000000018 DNA microarray Methods 0.000 claims description 9
- 238000003018 immunoassay Methods 0.000 claims description 9
- 108091023037 Aptamer Proteins 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 208000024777 Prion disease Diseases 0.000 claims description 7
- 206010036790 Productive cough Diseases 0.000 claims description 7
- 210000004381 amniotic fluid Anatomy 0.000 claims description 7
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 230000000762 glandular Effects 0.000 claims description 7
- 210000003097 mucus Anatomy 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 210000004910 pleural fluid Anatomy 0.000 claims description 7
- 238000003753 real-time PCR Methods 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 210000003802 sputum Anatomy 0.000 claims description 7
- 208000024794 sputum Diseases 0.000 claims description 7
- 210000001179 synovial fluid Anatomy 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- 102000015636 Oligopeptides Human genes 0.000 claims description 6
- 108010038807 Oligopeptides Proteins 0.000 claims description 6
- 208000037976 chronic inflammation Diseases 0.000 claims description 6
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 6
- 238000003795 desorption Methods 0.000 claims description 6
- 230000000951 immunodiffusion Effects 0.000 claims description 6
- 238000000760 immunoelectrophoresis Methods 0.000 claims description 6
- 238000012744 immunostaining Methods 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 238000000670 ligand binding assay Methods 0.000 claims description 6
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 6
- 238000001269 time-of-flight mass spectrometry Methods 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 208000030090 Acute Disease Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
- 102000014461 Ataxins Human genes 0.000 claims description 5
- 108010078286 Ataxins Proteins 0.000 claims description 5
- 206010003645 Atopy Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 5
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 5
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 5
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 5
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 5
- 208000001640 Fibromyalgia Diseases 0.000 claims description 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 206010065390 Inflammatory pain Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 5
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 208000034799 Tauopathies Diseases 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000009956 adenocarcinoma Diseases 0.000 claims description 5
- 208000004631 alopecia areata Diseases 0.000 claims description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims description 5
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 208000024908 graft versus host disease Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 201000010901 lateral sclerosis Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000005264 motor neuron disease Diseases 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 208000021722 neuropathic pain Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims description 5
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 5
- 208000005987 polymyositis Diseases 0.000 claims description 5
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006143 Brain stem glioma Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 4
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 4
- 206010034299 Penile cancer Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 206010046392 Ureteric cancer Diseases 0.000 claims description 4
- 206010046431 Urethral cancer Diseases 0.000 claims description 4
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 206010047741 Vulval cancer Diseases 0.000 claims description 4
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 4
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 201000007455 central nervous system cancer Diseases 0.000 claims description 4
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 230000002124 endocrine Effects 0.000 claims description 4
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000001343 fallopian tube carcinoma Diseases 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 4
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000002314 small intestine cancer Diseases 0.000 claims description 4
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 206010046885 vaginal cancer Diseases 0.000 claims description 4
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 4
- 201000004916 vulva carcinoma Diseases 0.000 claims description 4
- 208000013013 vulvar carcinoma Diseases 0.000 claims description 4
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 3
- 238000007823 electrophoretic assay Methods 0.000 claims 3
- 210000000019 nipple aspirate fluid Anatomy 0.000 claims 3
- 238000003127 radioimmunoassay Methods 0.000 claims 3
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 2
- 201000009385 autoimmune disease of the nervous system Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 27
- 230000002093 peripheral effect Effects 0.000 description 18
- 239000004055 small Interfering RNA Substances 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 108020004459 Small interfering RNA Proteins 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 210000003071 memory t lymphocyte Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 5
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000008157 ELISA kit Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710163270 Nuclease Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 230000001861 immunosuppressant effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000002445 nipple Anatomy 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- -1 for example Proteins 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000010801 machine learning Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 210000002501 natural regulatory T cell Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002715 modification method Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001046687 Homo sapiens Integrin alpha-E Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 241000545067 Venus Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- RHDXSLLGPJSSGW-VEGRVEBRSA-N phosphoric acid;(2r,3r,4r)-2,3,4,5-tetrahydroxypentanal Chemical group OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O RHDXSLLGPJSSGW-VEGRVEBRSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
Definitions
- Biomarkers for regulatory T cells ⁇ Biomarkers for regulatory T cells ⁇
- Regulatory T cells play an important role in naturally preventing the occurrence of excessive inflammation and immune response, but when autoimmune diseases and chronic inflammatory diseases occur, the function and number of regulatory T cells are significantly reduced. that has been reported Therefore, in the case of patients with immune and inflammatory diseases, it is important that regulatory T cells are produced at normal levels, and this can be one of the treatments for these diseases.
- regulatory T cells are abundantly distributed in the cancer microenvironment and inhibit the ability of natural killer cells (NK cells) or cancer-specific cytotoxic T lymphocytes to eliminate cancer cells. It has been reported to play an important role in the immune evasion mechanism of cancer along with 1 and CTLA-4.
- Regulatory T cells are naive regulatory T cells (undifferentiated Treg; nTreg), resting regulatory T cells (resting Treg; rTreg), effector Treg; eTreg), and memory regulatory T cells ( memory Treg; mTreg).
- the Shimon Sakaguchi group classified non-Treg, nTreg/rTreg, and eTreg based on the expression levels of CD4, CD45RA, Foxp3, and CD25 (CD4+CD25+CD45RA-Foxp3lo; non-Treg, CD4+CD25+CD45RA+Foxp3lo ; nTreg, CD4+CD25+CD45RA-Foxp3hi; eTreg).
- regulatory T cells action regulatory T cells and memory regulatory T cells are known to have high immunosuppressive ability.
- TIL tumor infiltrating lymphocytes
- One object of the present invention is to provide a method for identifying regulatory T cells using an antibody or antigen-binding fragment that specifically binds to a marker specific to regulatory T cells or a fragment thereof.
- Another object of the present invention is a marker specific to regulatory T cells or a fragment thereof; Or to provide a composition for diagnosis of cancer, immune-related disease or brain nervous system disease comprising an agent for measuring the expression level of a gene encoding the same.
- Another object of the present invention is a marker specific to regulatory T cells or a fragment thereof; Or to provide a diagnosis kit comprising a composition for diagnosis of cancer, immune-related disease or brain nervous system disease including an agent for measuring the expression level of a gene encoding the same.
- Another object of the present invention is a marker or fragment thereof specific to regulatory T cells in a biological sample isolated from a subject of interest; Or to provide an information providing method for diagnosing cancer, immune-related disease or brain nervous system disease comprising measuring the expression level of a gene encoding the same.
- Regulatory T cell or “Treg” of the present invention may be selected from the group consisting of regulatory T cells with high immunosuppressive activity, memory regulatory T cells, and cancer infiltrating lymphocyte regulatory T cells, but are limited thereto It is not.
- a "nucleic acid molecule" of the present invention includes any nucleic acid molecule in which the amino acid sequence of a polypeptide provided herein is translated into a polynucleotide sequence as known to those skilled in the art. Therefore, various polynucleotide sequences by ORF (open reading frame) can be prepared, and all of them are also included in the nucleic acid molecule of the present invention.
- ORF open reading frame
- antibody refers to a substance that specifically binds to an antigen and causes an antigen-antibody reaction.
- an antibody refers to an antibody that specifically binds to a regulatory T cell specific protein or an extracellular domain thereof.
- the antibodies of the present invention include both polyclonal antibodies, monoclonal antibodies and recombinant antibodies. Such antibodies can be readily prepared using techniques well known in the art. For example, polyclonal antibodies can be produced by a method well known in the art, which includes a process of injecting an antigen of the biomarker protein into an animal, collecting blood from the animal, and obtaining serum containing the antibody.
- polyclonal antibodies can be prepared from any animal, such as goat, rabbit, sheep, monkey, horse, pig, cow, dog, and the like.
- monoclonal antibodies can be prepared using the hybridoma method well known in the art (see Kohler and Milstein (1976) European Journal of Immunology 6:511-519), or the phage antibody library technique (Clackson et al, Nature, 352). :624-628, 1991; Marks et al, J. Mol. Biol., 222:58, 1-597, 1991).
- Antibodies prepared by the above methods may be separated and purified using methods such as gel electrophoresis, dialysis, salt precipitation, ion exchange chromatography, and affinity chromatography.
- antibodies of the present invention include functional fragments of antibody molecules as well as complete forms having two full-length light chains and two full-length heavy chains.
- a functional fragment of an antibody molecule means a fragment having at least an antigen-binding function, and includes Fab, F(ab'), F(ab')2, and Fv.
- immunoglobulin has a heavy chain and a light chain, each of which includes a constant region and a variable region.
- the light chain and heavy chain variable regions include three variable regions called complementarity determining regions (hereinafter referred to as “CDRs”) and four framework regions.
- CDRs complementarity determining regions
- the CDR mainly serves to bind to the antigenic determinant (Epitope) of the antigen.
- the CDRs of each chain are typically referred to sequentially starting from the N-terminus as CDR1, CDR2, and CDR3, and are also identified by the chain in which the particular CDR is located.
- the "complementarity determining region (CDR)" includes three variable regions and four framework regions.
- the CDR mainly serves to bind to the epitope of the antigen.
- the CDRs of each chain are typically referred to sequentially starting from the N-terminus as CDR1, CDR2, and CDR3, and are also identified by the chain in which the particular CDR is located.
- a "full-length antibody” is a structure having two full-length light chains and two full-length heavy chains, each light chain connected to the heavy chain by a disulfide bond, and IgA, IgD, IgE, IgM , and IgG.
- the IgG includes IgG1, IgG2, IgG3 and IgG4 as its subtype.
- antigen-binding fragment refers to a fragment having an antigen-binding function
- examples of antigen-binding fragments include (i) light chain variable region (VL) and heavy chain variable region (VH) and light chain constant region.
- the antigen-binding fragment may be a Fab or F(ab') 2 fragment using a proteolytic enzyme, for example, papain or pepsin, and may be prepared through genetic modifications.
- monoclonal antibody refers to an antibody molecule of a single molecular composition obtained from substantially the same antibody population, and exhibits a single binding specificity and affinity for a specific epitope.
- binding refers to the affinity of an antibody or antibody composition of the present invention for an antigen.
- “specific binding” is typically associated with non-specific background binding when the dissociation constant (Kd) is less than 1 x 10 -5 M or less than 1 x 10 -6 M or less than 1 x 10 -7 M can be distinguished.
- Kd dissociation constant
- Specific binding can be detected by methods known in the art, such as ELISA, surface plasmon resonance (SPR), immunoprecipitation, coprecipitation, and the like, and non-specific binding and specific binding Include an appropriate control group that can be differentiated.
- the "antibody or antigen-binding fragment" of the present invention may exist as a multimer such as a dimer, a trimer, a tetramer, or a pentamer, which includes at least a portion of the antigen-binding ability of a monomer. These multimers also include homomultimers or heteromultimers. Since antibody multimers contain multiple antigen-binding sites, they have superior antigen-binding ability compared to monomers. Multimers of antibodies are also easy to construct multifunctional (bifunctional, trifunctional, tetrafunctional) antibodies.
- prevention may include without limitation any act of blocking disease symptoms, suppressing or delaying disease symptoms using the pharmaceutical composition of the present invention.
- treatment and “improvement” may include without limitation any action that improves or benefits the symptoms of a disease by examining the pharmaceutical composition of the present invention.
- the "pharmaceutical composition” of the present invention is not limited to these, but is formulated in the form of oral formulations such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively.
- the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, flavors, etc. for oral administration, and buffers, preservatives, and painless agents for injections.
- the dosage form of the pharmaceutical composition of the present invention may be variously prepared by mixing with a pharmaceutically acceptable carrier as described above.
- a pharmaceutically acceptable carrier for example, for oral administration, it can be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and in the case of injections, it can be prepared in unit dosage ampoules or multiple dosage forms. there is.
- it may be formulated into solutions, suspensions, tablets, capsules, sustained-release preparations, and the like.
- examples of carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
- fillers, anti-coagulants, lubricants, wetting agents, flavoring agents, emulsifiers, preservatives, and the like may be further included.
- the "administration route" for the pharmaceutical composition includes, but is not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal , topical, sublingual or rectal. Oral or parenteral administration is preferred.
- parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intracapsular, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
- the pharmaceutical composition of the present invention may also be administered in the form of a suppository for rectal administration.
- the "use and dose” of the composition of the present invention includes the activity of the specific compound used, age, weight, general health, gender, dosage, administration time, route of administration, excretion rate, drug formulation and severity of the specific disease to be prevented or treated. It can vary widely depending on various factors, and the dosage of the pharmaceutical composition varies depending on the patient's condition, weight, disease severity, drug type, administration route and period, but can be appropriately selected by those skilled in the art, and can be appropriately selected by a person skilled in the art, 0.0001 per day. to 50 mg/kg or 0.001 to 50 mg/kg. Administration may be administered once a day, or may be administered in several divided doses. The dosage is not intended to limit the scope of the present invention in any way.
- the pharmaceutical composition according to the present invention may be formulated into a pill, dragee, capsule, liquid, gel, syrup, slurry, or suspension.
- PNA Protein Nucleic Acid
- PNA Peptide Nucleic Acid
- DNA has a phosphate-ribose backbone
- PNA has a repeated N-(2-aminoethyl)-glycine backbone linked by peptide bonds, which greatly increases the binding force and stability to DNA or RNA, and is thus used in molecular biology. , diagnostic assays and antisense therapies.
- PNA is described by Nielsen PE, Egholm M, Berg RH, Buchardt O (December 1991). "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide". Science 254 (5037): 1497-1500.
- An "aptamer” of the present invention is an oligonucleic acid or peptide molecule, and a general description of aptamers is described in Bock LC et al., Nature 355(6360):5646 (1992); Hoppe-Seyler F, Butz K "Peptide aptamers: powerful new tools for molecular medicine”. J Mol Med. 78(8):42630 (2000); Cohen BA, Colas P, Brent R. "An artificial cell-cycle inhibitor isolated from a combinatorial library”. Proc Natl Acad Sci USA. 95(24): 142727 (1998).
- the "primer” of the present invention is a fragment that recognizes a target gene sequence, and includes a forward and reverse primer pair, preferably a primer pair that provides an analysis result having specificity and sensitivity. High specificity can be imparted when the nucleic acid sequence of the primer is a sequence that is inconsistent with the non-target sequence present in the sample, so that the primer amplifies only the target gene sequence containing a complementary primer binding site and does not cause non-specific amplification. .
- probe of the present invention means a substance capable of specifically binding to a target substance to be detected in a sample, and means a substance capable of specifically confirming the presence of a target substance in a sample through the binding.
- the type of probe is not limited as a material commonly used in the art, but preferably may be peptide nucleic acid (PNA), locked nucleic acid (LNA), peptide, polypeptide, protein, RNA or DNA, and most preferably Most likely it is PNA.
- PNA peptide nucleic acid
- LNA locked nucleic acid
- the probe is a biomaterial, including one derived from or similar to a living organism or manufactured in vitro, for example, enzymes, proteins, antibodies, microorganisms, animal and plant cells and organs, nerve cells, DNA, and It may be RNA, DNA includes cDNA, genomic DNA, and oligonucleotides, RNA includes genomic RNA, mRNA, and oligonucleotides, and examples of proteins may include antibodies, antigens, enzymes, peptides, and the like.
- LNA Locked nucleic acids
- LNA nucleosides contain the common nucleic acid bases of DNA and RNA, and can base pair according to the Watson-Crick base pairing rules. However, due to molecular 'locking' due to the methylene bridge, the LNA does not form an ideal shape in the Watson-Crick bond.
- LNAs When LNAs are included in DNA or RNA oligonucleotides, they can more rapidly pair with complementary nucleotide chains to increase the stability of the double helix.
- the "antisense” of the present invention is a sequence of nucleotide bases in which an antisense oligomer hybridizes with a target sequence in RNA by Watson-Crick base pairing, allowing the formation of typically mRNA and RNA:oligomeric heteroduplexes in the target sequence, and It refers to an oligomer having an inter-subunit backbone. Oligomers may have exact sequence complementarity or near complementarity to the target sequence.
- the "kit” of the present invention may be an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid kit, or a multiple reaction monitoring (MRM) kit, but is not limited thereto.
- the diagnostic kit may further include one or more other constituent compositions, solutions or devices suitable for the assay method. For example, it may further include essential elements necessary for carrying out the reverse transcription polymerase reaction.
- the reverse transcription polymerase reaction kit contains a pair of primers specific for a gene encoding a marker protein.
- the primer is a nucleotide having a sequence specific to the nucleic acid sequence of the gene, and may have a length of about 7 bp to 50 bp, more preferably about 10 bp to 30 bp.
- a primer specific for the nucleic acid sequence of the control gene may be included.
- Other reverse transcription polymerase reaction kits contain a test tube or other suitable container, reaction buffer (with varying pH and magnesium concentration), deoxynucleotides (dNTPs), enzymes such as Taq-polymerase and reverse transcriptase, DNase and RNase inhibitor DEPC. -Water (DEPC-water), sterilized water, etc. may be included.
- the kit for diagnosis may include essential elements required to perform the DNA chip.
- the DNA chip kit may include a substrate to which cDNA or oligonucleotides corresponding to genes or fragments thereof are attached, and reagents, reagents, enzymes, and the like for producing fluorescently labeled probes.
- the substrate may include a cDNA or oligonucleotide corresponding to a control gene or a fragment thereof.
- the diagnostic kit may include essential elements required to perform ELISA.
- ELISA kits contain antibodies specific for the protein.
- An antibody is an antibody that has high specificity and affinity for a marker protein and little cross-reactivity to other proteins, and is a monoclonal antibody, polyclonal antibody, or recombinant antibody.
- ELISA kits may also include antibodies specific for a control protein.
- Other ELISA kits include reagents capable of detecting bound antibodies, such as labeled secondary antibodies, chromophores, enzymes (eg, conjugated with antibodies) and substrates thereof or those capable of binding the antibody. may contain other substances and the like.
- the "object of interest" of the present invention refers to an individual whose onset of a disease is uncertain and has a high possibility of developing the disease.
- the "biological sample” of the present invention means any material, biological fluid, tissue or cell obtained from or derived from an individual, for example, whole blood, leukocytes, peripheral blood mononuclear Peripheral blood mononuclear cells, buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirates (nasal aspirate), breath, urine, semen, saliva, peritoneal washings, pelvic fluids, cystic fluid, meningeal fluid (meningeal fluid), amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate , synovial fluid, joint aspirate, organ secretions, cells, cell extracts, or cerebrospinal fluid, but is not limited thereto. .
- test substance includes any substance, molecule, element, compound, entity, or combination thereof. Examples include, but are not limited to, proteins, polypeptides, small organic molecules, polysaccharides, polynucleotides, and the like. It may also be a natural product, a synthetic compound or a combination of two or more substances.
- the composition of the present invention may include, in addition to the protein, a buffer or reaction solution stably maintaining the structure or physiological activity of the protein.
- the composition of the present invention may include, for in vivo experiments, cells expressing the protein, or cells containing a plasmid expressing the protein under a promoter capable of controlling transcription.
- the test substance may be an individual nucleic acid, protein, other extract or natural product, compound, etc.
- an immunosuppressant candidate material can be developed by developing an inhibitor for the test substance, and in the latter case, an immunosuppressant candidate material can be made.
- an immunosuppressant candidate material serves as a leading compound in the subsequent immunosuppressant development process, and by modifying and optimizing its structure so that the lead material can exhibit the effect of inhibiting the function of the gene or the protein expressed therefrom. , can develop new immunosuppressive agents.
- siRNA small interfering RNA
- the "siRNA (small interfering RNA)" of the present invention is a short double strand RNA duplex of 19-30 that, when introduced into cells, has the effect of inhibiting only the expression of a specific gene without non-specific inhibition.
- the mechanism of action of siRNA is that the sense strand of the gene corresponding to the mRNA is cut off by binding to RISC (RNA-induced silencing complex) in the cell, and the antisense stand complementary to the sense strand is in a complex with RISC and then has a complementary base sequence It is known to inhibit the expression of a gene by binding to and degrading mRNA with a target gene.
- RISC RNA-induced silencing complex
- the "shRNA (short hairpin RNA)" of the present invention synthesizes an oligo DNA linking a 310 base linker between the sense and complementary nonsense of the target gene siRNA sequence, and then clones it into a plasmid vector or shRNA into a retrovirus When inserted into lentivirus and adenovirus and expressed, shRNA with a looped hairpin structure is created and converted to siRNA by Dicer in the cell to show RNAi effect.
- shRNA has a relatively long-term RNAi effect It has the advantage of showing .
- the siRNA of the present invention may be in a chemically modified form to prevent rapid degradation by in vivo nucleases.
- siRNA Since siRNA has a double helix structure, it is relatively more stable than single helix ribonucleic acid or antisense oligonucleotide, but it is rapidly degraded by nucleases in vivo, so the degradation rate can be reduced through chemical modification. there is.
- Methods for chemically modifying siRNA to make it stable and resistant to degradation are well known to those skilled in the art. The most commonly used method for chemical modification of siRNA is boranophosphate or phosphorothioate modification. These materials stably form linkages between nucleoside of siRNA, resulting in resistance to nucleic acid degradation.
- ribonucleic acid modified with boranophosphate is characterized by poor nucleic acid degradation, it is synthesized only in such a way that ranophosphate enters ribonucleic acid by an in vitro transcription reaction rather than being produced by a chemical reaction.
- the boranophosphate modification method belongs to a relatively easy method, but has a disadvantage in that it is difficult to modify a specific location.
- the phosphorothioate modification method has the advantage of introducing elemental sulfur to the desired part, but severe phosphorothioation causes reduced efficacy, toxicity, formation of non-specific RISC (RNAinduced silencing complex), etc. problems may appear.
- siRNA of the present invention may be included in a pharmaceutical composition for cancer treatment in the form of a complex with a nucleic acid delivery system.
- cancer refers to or refers to a physiological condition typically characterized by unregulated cell growth in mammals.
- Cancer to be prevented, improved, or treated in the present invention may be a solid tumor formed by the abnormal growth of cells in a solid organ, and depending on the site of the solid organ, gastric cancer, liver cancer, It may be glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, but is not limited thereto.
- immune-related disease may be at least one selected from the group consisting of autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, and acute or chronic inflammatory disease, but is limited thereto It is not.
- the autoimmune disease is rheumatoid arthritis, systemic scleroderma, systemic lupus erythematosus, atopic dermatitis, psoriasis, alopecia areata, asthma, Crohn's disease, Behçetshi's disease, Sjogren's syndrome, Gilia-Barre syndrome, chronic thyroiditis, multiple sclerosis, It may be one or more selected from the group consisting of polymyositis, ankylosing spondylitis, fibromyalgia and polyarteritis nodosa, but is not limited thereto.
- Cerebral nervous system disease may be a neurodegenerative disease or a neuroinflammatory disease.
- the "neurodegenerative disease” may refer to a disease caused by reduced or lost function of nerve cells
- the "neuroinflammatory disease” may refer to a disease caused by an excessive inflammatory response of the nervous system. there is.
- neurodegenerative disease or neuroinflammatory disease in the present invention include stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Niemann-Pick disease , multiple sclerosis, prion disease, Creutzfeldt-Jakob disease, frontotemporal dementia, Lewy dementia, AlzAmyotrophic lateral sclerosis, paraneoplastic syndrome, corticobasal degeneration multiple system atrophy, progressive supranuclear palsy, autoimmune diseases of the nervous system, spinocerebellar ataxia, inflammatory and neuropathic pain, cerebrovascular disease, spinal cord injury and tauopathy. It may be selected from the group, but is not limited thereto.
- the term "method for identifying regulatory T cells” refers to amplifying specific markers present in regulatory T cells through reverse transcription polymerase chain reaction (RT-PCR) and performing flow cytometry (fluorescence activated cell reaction). sorting, FACS), etc., to confirm specific markers present in regulatory T cells through fluorescence, thereby identifying or isolating regulatory T cells, but is not limited thereto.
- reverse transcription polymerase reaction is a modification of the polymerase chain reaction (PCR), an experimental technique commonly used in molecular biology to create a large number of DNA sequences through an amplification process. am.
- PCR polymerase chain reaction
- RNA is first reverse-transcribed by reverse transcriptase to make cDNA, and the produced cDNA is amplified through conventional polymerase chain reaction or real-time polymerase chain reaction, but is not limited thereto.
- the "fluorescence activated cell sorting (FACS)" refers to the sorting of one or more populations of cells according to the presence, absence or level of selectable polypeptides in one or more FACS expressed by the cells. Means how to separate into sub-populations.
- the FACS relies on optical properties, including fluorescence, of individual cells to classify cells into subpopulations.
- the "FACS selectable polypeptide” is a polypeptide that can be directly or indirectly detected by flow cytometry.
- FACS selectable polypeptides include extracellular domains (eg, CD52 or CD59) that can be linked to a detectable binding partner (eg, a fluorescently labeled antibody) for indirect detection of the polypeptide by flow cytometry.
- Other examples of FACS selectable polypeptides include polypeptides comprising fluorescent proteins such as green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), blue fluorescent protein (BFP) and and variants thereof including eGFP, Venus, mCherry, and mTomato, which can be directly detected by the flow cytometry.
- GFP green fluorescent protein
- RFP red fluorescent protein
- YFP yellow fluorescent protein
- BFP blue fluorescent protein
- One embodiment of the present invention is RGS1; Provided is a method for identifying regulatory T cells with an antibody or antigen-binding fragment that specifically binds to any one protein or fragment thereof selected from the group consisting of F5 and CD27.
- Another embodiment of the present invention provides a method for identifying regulatory T cells, wherein the protein is a cell surface protein specifically expressed on the surface of regulatory T cells.
- Another embodiment of the present invention is a method for identifying regulatory T cells, wherein the regulatory T cells are cell surface proteins including at least one member from the group consisting of functional regulatory T cells, memory regulatory T cells, and cancer infiltrating lymphocyte regulatory T cells.
- One embodiment of the present invention is RGS1; Any one protein or fragment thereof selected from the group consisting of F5 and CD27; Or it provides a composition for diagnosis of cancer disease comprising an agent for measuring the expression level of the gene encoding it.
- Another embodiment of the present invention provides a composition for diagnosis, wherein the protein is a cell surface protein specifically expressed on the surface of regulatory T cells.
- Another embodiment of the present invention provides a diagnostic composition in which the regulatory T cells are cell surface proteins including at least one member from the group consisting of functional regulatory T cells, memory regulatory T cells, and cancer infiltrating lymphocyte regulatory T cells.
- the agent for measuring the expression level of the protein or fragment thereof is an antibody, oligopeptide, ligand, PNA (peptide nucleic acid) and aptamer that specifically bind to the protein or fragment thereof It provides a diagnostic composition comprising at least one member selected from the group consisting of.
- the agent for measuring the expression level of the gene encoding the protein or fragment thereof comprises at least one selected from the group consisting of primers, probes, and antisense nucleotides that specifically bind to the gene, A composition for diagnosis is provided.
- the cancer is ovarian cancer, colorectal cancer, pancreatic cancer, gastric cancer, liver cancer, breast cancer, cervical cancer, thyroid cancer, parathyroid cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, biliary tract cancer, and non-Hodgkin's lymphoma.
- Hodgkin's lymphoma Hodgkin's lymphoma, blood cancer, bladder cancer, kidney cancer, melanoma, colon cancer, bone cancer, skin cancer, head cancer, uterine cancer, rectal cancer, brain tumor, perianal cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal cancer, vulvar carcinoma, esophageal cancer, small intestine Cancer, endocrine adenocarcinoma, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, ureteral cancer, renal cell carcinoma, renal pelvic carcinoma, CNS central nervous system tumor, primary CNS lymphoma, spinal cord tumor, brainstem glioma or pituitary gland
- a composition for diagnosis of an adenoma is provided.
- Another embodiment of the present invention provides a kit for diagnosing cancer disease comprising the composition for diagnosis.
- One embodiment of the present invention is RGS1 in a biological sample isolated from a subject of interest; Any one protein or fragment thereof selected from the group consisting of F5 and CD27; Or it provides an information providing method for diagnosing cancer disease comprising measuring the expression level of a gene encoding the same.
- Another embodiment of the present invention provides a method for providing information, wherein the protein is a cell surface protein specifically expressed on the surface of regulatory T cells.
- Another embodiment of the present invention provides a method for providing information, wherein the regulatory T cells are cell surface proteins including at least one member from the group consisting of functional regulatory T cells, memory regulatory T cells, and cancer infiltrating lymphocyte regulatory T cells.
- the biological sample is whole blood, leukocytes, peripheral blood mononuclear cells, leukocyte buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, Peritoneal washings, pelvic fluids, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid ( lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cell ), a cell extract or cerebrospinal fluid is provided.
- the method for measuring the expression level of the protein or fragment thereof includes protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, SELDI -TOF (Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, radiation immunoassay, radioimmunodiffusion method, Oukteroni immunodiffusion method, rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis analysis , liquid chromatography-mass spectrometry (LC-MS), LC-MS/MS (liquid chromatography-Mass Spectrometry/ Mass Spectrometry), Western blotting, or ELISA (enzyme linked immunosorbentassay), Provides a way to provide information.
- MALDI-TOF Microx Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry
- the method for measuring the expression level of the gene encoding the protein or fragment thereof is reverse transcription polymerase reaction (RT-PCR), competitive reverse transcription polymerase reaction (Competitive RT-PCR), real-time reverse transcription polymerase Reaction (Real-time RT-PCR), RNase protection assay (RPA; RNase protection assay), Northern blotting (Northern blotting), or performed by DNA chip, an information providing method is provided.
- RT-PCR reverse transcription polymerase reaction
- Competitive RT-PCR competitive reverse transcription polymerase reaction
- Real-time RT-PCR real-time reverse transcription polymerase Reaction
- RNase protection assay RNase protection assay
- Northern blotting Northern blotting
- DNA chip an information providing method is provided.
- the cancer is ovarian cancer, colorectal cancer, pancreatic cancer, gastric cancer, liver cancer, breast cancer, cervical cancer, thyroid cancer, parathyroid cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, biliary tract cancer, and non-Hodgkin's lymphoma.
- Hodgkin's lymphoma Hodgkin's lymphoma, blood cancer, bladder cancer, kidney cancer, melanoma, colon cancer, bone cancer, skin cancer, head cancer, uterine cancer, rectal cancer, brain tumor, perianal cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal cancer, vulvar carcinoma, esophageal cancer, small intestine Cancer, endocrine adenocarcinoma, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, ureteral cancer, renal cell carcinoma, renal pelvic carcinoma, CNS central nervous system tumor, primary CNS lymphoma, spinal cord tumor, brainstem glioma or pituitary gland It is a Zen species, and provides a method of providing information.
- One embodiment of the present invention is RGS1; Any one protein or fragment thereof selected from the group consisting of F5 and CD27; Or it provides a composition for diagnosis of immune-related diseases comprising an agent for measuring the expression level of a gene encoding the same.
- Another embodiment of the present invention provides a composition for diagnosis, wherein the protein is a cell surface protein specifically expressed on the surface of regulatory T cells.
- Another embodiment of the present invention provides a diagnostic composition in which the regulatory T cells are cell surface proteins including at least one member from the group consisting of functional regulatory T cells, memory regulatory T cells, and cancer infiltrating lymphocyte regulatory T cells.
- the agent for measuring the expression level of the protein or fragment thereof is an antibody, oligopeptide, ligand, PNA (peptide nucleic acid) and aptamer that specifically bind to the protein or fragment thereof It provides a diagnostic composition comprising at least one member selected from the group consisting of.
- the agent for measuring the expression level of the gene encoding the protein or fragment thereof comprises at least one selected from the group consisting of primers, probes, and antisense nucleotides that specifically bind to the gene, A composition for diagnosis is provided.
- the immune-related disease is an autoimmune disease; graft-versus-host disease; organ transplant rejection; asthma; atopy; Or an acute or chronic inflammatory disease, provides a composition for diagnosis.
- the autoimmune disease is rheumatoid arthritis, systemic scleroderma, systemic lupus erythematosus, atopic dermatitis, psoriasis, alopecia areata, asthma, Crohn's disease, Bechetsy's disease, Sjogren's syndrome, Guilla-Barre syndrome, chronic Provided is a diagnostic composition selected from the group consisting of thyroiditis, multiple sclerosis, polymyositis, ankylosing spondylitis, fibromyalgia and polyarteritis nodosa.
- Another embodiment of the present invention provides a kit for diagnosing an immune-related disease comprising the composition for diagnosis.
- One embodiment of the present invention is RGS1 in a biological sample isolated from a subject of interest; Any one protein or fragment thereof selected from the group consisting of F5 and CD27; Or it provides an information providing method for diagnosing cancer disease comprising measuring the expression level of a gene encoding the same.
- Another embodiment of the present invention provides a method for providing information, wherein the protein is a cell surface protein specifically expressed on the surface of regulatory T cells.
- Another embodiment of the present invention provides a method for providing information, wherein the regulatory T cells are cell surface proteins including at least one member from the group consisting of functional regulatory T cells, memory regulatory T cells, and cancer infiltrating lymphocyte regulatory T cells.
- the biological sample is whole blood, leukocytes, peripheral blood mononuclear cells, leukocyte buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, Peritoneal washings, pelvic fluids, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid ( lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cell ), a cell extract or cerebrospinal fluid is provided.
- the method for measuring the expression level of the protein or fragment thereof includes protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, SELDI -TOF (Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, radiation immunoassay, radioimmunodiffusion method, Oukteroni immunodiffusion method, rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis analysis , liquid chromatography-mass spectrometry (LC-MS), LC-MS/MS (liquid chromatography-Mass Spectrometry/ Mass Spectrometry), Western blotting, or ELISA (enzyme linked immunosorbentassay), Provides a way to provide information.
- MALDI-TOF Microx Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry
- the method for measuring the expression level of the gene encoding the protein or fragment thereof is reverse transcription polymerase reaction (RT-PCR), competitive reverse transcription polymerase reaction (Competitive RT-PCR), real-time reverse transcription polymerase Reaction (Real-time RT-PCR), RNase protection assay (RPA; RNase protection assay), Northern blotting (Northern blotting), or performed by DNA chip, an information providing method is provided.
- RT-PCR reverse transcription polymerase reaction
- Competitive RT-PCR competitive reverse transcription polymerase reaction
- Real-time RT-PCR real-time reverse transcription polymerase Reaction
- RNase protection assay RNase protection assay
- Northern blotting Northern blotting
- DNA chip an information providing method is provided.
- the immune-related disease is an autoimmune disease; graft-versus-host disease; organ transplant rejection; asthma; atopy; Or an acute or chronic inflammatory disease, an information providing method is provided.
- the autoimmune disease is rheumatoid arthritis, systemic scleroderma, systemic lupus erythematosus, atopic dermatitis, psoriasis, alopecia areata, asthma, Crohn's disease, Bechetsy's disease, Sjogren's syndrome, Guilla-Barre syndrome, chronic Provided is an information providing method selected from the group consisting of thyroiditis, multiple sclerosis, polymyositis, ankylosing spondylitis, fibromyalgia and polyarteritis nodosa.
- One embodiment of the present invention is RGS1; Any one protein or fragment thereof selected from the group consisting of F5 and CD27; Or it provides a composition for diagnosis of a brain nervous system disease comprising an agent for measuring the expression level of the gene encoding it.
- Another embodiment of the present invention provides a composition for diagnosis, wherein the protein is a cell surface protein specifically expressed on the surface of regulatory T cells.
- Another embodiment of the present invention provides a diagnostic composition in which the regulatory T cells are cell surface proteins including at least one member from the group consisting of functional regulatory T cells, memory regulatory T cells, and cancer infiltrating lymphocyte regulatory T cells.
- the agent for measuring the expression level of the protein or fragment thereof is an antibody, oligopeptide, ligand, PNA (peptide nucleic acid) and aptamer that specifically bind to the protein or fragment thereof It provides a diagnostic composition comprising at least one member selected from the group consisting of.
- the agent for measuring the expression level of the gene encoding the protein or fragment thereof comprises at least one selected from the group consisting of primers, probes, and antisense nucleotides that specifically bind to the gene, A composition for diagnosis is provided.
- Another embodiment of the present invention provides a composition for diagnosis, wherein the brain nervous system disease is a neurodegenerative disease or a neuroinflammatory disease.
- the neurodegenerative disease or neuroinflammatory disease is stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Niemann-Pick disease , multiple sclerosis, prion disease, Creutzfeldt-Jakob disease, frontotemporal dementia, Lewy dementia, AlzAmyotrophic lateral sclerosis, paraneoplastic syndrome, corticobasal degeneration multiple system atrophy, progressive supranuclear palsy, autoimmune diseases of the nervous system, spinocerebellar ataxia, inflammatory and neuropathic pain, cerebrovascular disease, spinal cord injury and tauopathy. It provides a diagnostic composition selected from the group.
- Another embodiment of the present invention provides a kit for diagnosing a brain nervous system disease comprising the composition for diagnosis.
- One embodiment of the present invention is RGS1 in a biological sample isolated from a subject of interest; Any one protein or fragment thereof selected from the group consisting of F5 and CD27; Or it provides an information providing method for diagnosing a brain nervous system disease comprising the step of measuring the expression level of the gene encoding it.
- Another embodiment of the present invention provides a method for providing information, wherein the protein is a cell surface protein specifically expressed on the surface of regulatory T cells.
- Another embodiment of the present invention provides a method for providing information, wherein the regulatory T cells are cell surface proteins including at least one member from the group consisting of functional regulatory T cells, memory regulatory T cells, and cancer infiltrating lymphocyte regulatory T cells.
- the biological sample is whole blood, leukocytes, peripheral blood mononuclear cells, leukocyte buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, Peritoneal washings, pelvic fluids, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid ( lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cell ), a cell extract or cerebrospinal fluid is provided.
- the method for measuring the expression level of the protein or fragment thereof includes protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, SELDI -TOF (Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, radiation immunoassay, radioimmunodiffusion method, Oukteroni immunodiffusion method, rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis analysis , liquid chromatography-mass spectrometry (LC-MS), LC-MS/MS (liquid chromatography-Mass Spectrometry/ Mass Spectrometry), Western blotting, or ELISA (enzyme linked immunosorbentassay), Provides a way to provide information.
- MALDI-TOF Microx Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry
- the method for measuring the expression level of the gene encoding the protein or fragment thereof is reverse transcription polymerase reaction (RT-PCR), competitive reverse transcription polymerase reaction (Competitive RT-PCR), real-time reverse transcription polymerase Reaction (Real-time RT-PCR), RNase protection assay (RPA; RNase protection assay), Northern blotting (Northern blotting), or performed by DNA chip, an information providing method is provided.
- RT-PCR reverse transcription polymerase reaction
- Competitive RT-PCR competitive reverse transcription polymerase reaction
- Real-time RT-PCR real-time reverse transcription polymerase Reaction
- RNase protection assay RNase protection assay
- Northern blotting Northern blotting
- DNA chip an information providing method is provided.
- Another embodiment of the present invention provides a method for providing information, wherein the cranial nervous system disease is a neurodegenerative disease or a neuroinflammatory disease.
- the neurodegenerative disease or neuroinflammatory disease is stroke, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Niemann-Pick disease , multiple sclerosis, prion disease, Creutzfeldt-Jakob disease, frontotemporal dementia, Lewy dementia, AlzAmyotrophic lateral sclerosis, paraneoplastic syndrome, corticobasal degeneration multiple system atrophy, progressive supranuclear palsy, autoimmune diseases of the nervous system, spinocerebellar ataxia, inflammatory and neuropathic pain, cerebrovascular disease, spinal cord injury and tauopathy.
- An information providing method selected from the group is provided.
- Regulatory T cells can be selected using the marker protein specific for regulatory T cells or a fragment thereof of the present invention in that it is a factor that can be distinguished from other immune cells. Also by identifying regulatory T cells that express specific markers for the regulatory T cells, the regulatory T cells affect; cancer; immune related diseases; Alternatively, a cranial nervous system disease may be diagnosed.
- XGBoost Extreme Gradient Boosting
- Example 1 T regulatory cell biomarker screening in colorectal cancer (CRC)
- the disaggregated tissue was passed through a 40 ⁇ m cell-strainer and centrifuged at 400 g for 10 minutes.
- cDNA was synthesized by reverse transcriptase PCR using the Smart-Seq2 (Nat Protoc. 2014 Jan;9(1):171-81) method, and mRNA expression levels were measured by qPCR.
- the T cell subsets used in the analysis were tumor Treg, peripheral Treg, Th17, effector memory T cell and naive T cell.
- the number of cells used in the analysis was 10,805 cells (data for 12,525 genes) out of 11,138 single cells.
- TPM Transcript per million
- Tumor Treg 1,319 cells
- Tumor Treg cells and other cell subsets were distinguished:
- Tumor Treg cluster 1,319 single cells
- Non-tumor Treg cluster 1,270 single cells
- TPM values for all single cells were entered into XGBoost to generate a conditional algorithm that can most efficiently divide tumor Tregs and other T cell subsets.
- the number of genes used for the condition was 474.
- Treg-specific markers were selected based on the following detailed strategies.
- Example 1 Single cell sorting and reverse transcription, amplification and sequencing were performed in the same manner as in Example 1.
- tumor Tregs tumor Tregs, peripheral Tregs, undifferentiated T cells, cytotoxic CD4, and exhausted T cells were used as the T cell subsets used in the analysis.
- the number of cells used in the analysis was 5,063 single cells (data for 23,389 genes).
- Undifferentiated T cells 646 cells;
- Tumor Treg rankings and different cell subsets were distinguished:
- Non-tumor Treg cluster 1,220 single cells
- TPM values for all single cells were entered into XGBoost to generate a conditional algorithm that can most efficiently divide tumor Tregs and other T cell subsets. At this time, the number of genes used for the condition was 281.
- Treg-specific markers were selected based on the following detailed strategies.
- T cell subsets used in the analysis were tumor Treg, peripheral Treg, undifferentiated T cell, cytotoxic CD4, exhausted T cell, central memory T cell, and effector memory T cell. Memory T cell) was used.
- the number of cells used in the analysis was 12,346 single cells (data for 12,394 genes).
- Undifferentiated T cells 532 cells;
- Tumor Treg rankings and different cell subsets were distinguished:
- Non-tumor Treg cluster 2,398 single cells
- TPM values for all single cells were entered into XGBoost to generate a conditional algorithm that can most efficiently divide tumor Tregs and other T cell subsets.
- the number of genes used for the condition was 548.
- Treg-specific markers were selected based on the following detailed strategies.
- Scenario 1 A gene whose TPM value of tumor Treg cells is higher than that of undifferentiated T cells
- 2Scenario 2 Genes whose TPM values in peripheral Treg cells are higher than TPM values in undifferentiated T cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
F5 | Treg 세포 | 말초 Treg | 지친 T세포 | 세포독성 CD4 | 미분화 T 세포 |
CRC | 3.100195011 | -0.399058546 | -0.914322388 | -0.580858528 | |
HCC | 76.68346154 | 7.718967563 | 13.65846679 | ||
NSCLC | 2.971520357 | -0.737334345 | -0.384756266 | 0.389661106 | 2.108812156 |
CD27 | Treg 세포 | 말초 Treg | 지친 T세포 | 세포독성 CD4 | 미분화 T 세포 |
CRC | 2.499269581 | -2.405700303 | 1.575739572 | 1.529513703 | |
HCC | 1719.785654 | 516.3749448 | 761.0570309 | ||
NSCLC | 3.282889886 | -3.151742758 | 1.350902944 | 0.484835081 | 2.482556123 |
RGS1 | Treg 세포 | 말초 Treg | 지친 T세포 | 세포독성 CD4 | 미분화 T 세포 |
CRC | 3.517801886 | 3.540307286 | 2.20818689 | -5.350675572 | |
HCC | 3801.927585 | 5962.456581 | 84.52466424 | ||
NSCLC | 3.662258478 | -3.686078393 | -3.882425395 | 4.515817357 | -0.340774184 |
Claims (49)
- RGS1; F5 및 CD27 로 구성된 군으로부터 선택된 어느 하나의 단백질 또는 이의 단편에 특이적으로 결합하는 항체 또는 항원 결합 단편으로 조절 T 세포를 확인하는 방법.
- 제 1항에 있어서,상기 단백질은 조절 T 세포의 표면에 특이적으로 발현하는 세포표면 단백질인, 조절 T 세포를 확인하는 방법.
- 제 1항에 있어서,상기 조절 T 세포는 작용 조절 T 세포, 기억 조절 T 세포, 암 침윤 림프구 조절 T 세포로 이루어진 군에서 1종 이상이 포함되는 세포표면 단백질인, 조절 T 세포를 확인하는 방법.
- RGS1; F5 및 CD27로 구성된 군으로부터 선택된 어느 하나의 단백질 또는 이의 단편; 또는 이를 암호화하는 유전자의 발현 수준을 측정하는 제제를 포함하는 암 질환의 진단용 조성물.
- 제 4항에 있어서,상기 단백질은 조절 T 세포의 표면에 특이적으로 발현하는 세포표면 단백질인, 진단용 조성물.
- 제 5항에 있어서,상기 조절 T 세포는 작용 조절 T 세포, 기억 조절 T 세포, 암 침윤 림프구 조절 T 세포로 이루어진 군에서 1종 이상이 포함되는 세포표면 단백질인, 진단용 조성물.
- 제 4항에 있어서,상기 단백질 또는 이의 단편의 발현 수준을 측정하는 제제는 상기 단백질 또는 이의 단편에 특이적으로 결합하는 항체, 올리고펩타이드, 리간드, PNA(peptide nucleic acid) 및 앱타머(aptamer)로 이루어진 군에서 선택된 1종 이상을 포함하는, 진단용 조성물.
- 제 4항에 있어서,상기 단백질 또는 이의 단편을 암호화하는 유전자의 발현 수준을 측정하는 제제는 상기 유전자에 특이적으로 결합하는 프라이머, 프로브 및 안티센스 뉴클레오티드로 이루어진 군에서 선택된 1종 이상을 포함하는, 진단용 조성물.
- 제 4항 내지 제 8항 중 어느 한 항에 있어서,상기 암은 난소암, 대장암, 췌장암, 위암, 간암, 유방암, 자궁경부암, 갑상선암, 부갑상선암, 폐암, 비소세포성폐암, 전립선암, 담낭암, 담도암, 비호지킨 림프종, 호지킨 림프종, 혈액암, 방광암, 신장암, 흑색종, 결장암, 골암, 피부암, 두부암, 자궁암, 직장암, 뇌종양, 항문부근암, 나팔관암종, 자궁내막암종, 질암, 음문암종, 식도암, 소장암, 내분비선암, 부신암, 연조직 육종, 요도암, 음경암, 수뇨관암, 신장세포 암종, 신장골반 암종, 중추신경계(CNS central nervoussystem) 종양, 1차 CNS 림프종, 척수 종양, 뇌간 신경교종 또는 뇌하수체 선종인, 진단용 조성물.
- 제 4항 내지 제 9항 중 어느 한 항의 진단용 조성물을 포함하는 암 질환 진단용 키트.
- 목적하는 개체로부터 분리된 생물학적 시료에서 RGS1; F5 및 CD27로 구성된 군으로부터 선택된 어느 하나의 단백질 또는 이의 단편; 또는 이를 암호화하는 유전자의 발현 수준을 측정하는 단계를 포함하는 암 질환을 진단하기 위한 정보 제공 방법.
- 제 11항에 있어서,상기 단백질은 조절 T 세포의 표면에 특이적으로 발현하는 세포표면 단백질인, 정보 제공 방법.
- 제 12항에 있어서,상기 조절 T 세포는 작용 조절 T 세포, 기억 조절 T 세포, 암 침윤 림프구 조절 T 세포로 이루어진 군에서 1종 이상이 포함되는 세포표면 단백질인, 정보 제공 방법.
- 제 13항에 있어서,상기 생물학적 시료는 전혈(whole blood), 백혈구(leukocytes), 말초혈액 단핵 세포(peripheral blood mononuclear cells), 백혈구 연층(buffy coat), 혈장(plasma), 혈청(serum), 객담(sputum), 눈물(tears), 점액(mucus), 세비액(nasal washes), 비강 흡인물(nasal aspirate), 호흡(breath), 소변(urine), 정액(semen), 침(saliva), 복강 세척액(peritoneal washings), 골반 내 유체액(pelvic fluids), 낭종액(cystic fluid), 뇌척수막 액(meningeal fluid), 양수(amniotic fluid), 선액(glandular fluid), 췌장액(pancreatic fluid), 림프액(lymph fluid), 흉수(pleural fluid), 유두 흡인물(nipple aspirate), 기관지 흡인물(bronchial aspirate), 활액(synovial fluid), 관절 흡인물(joint aspirate), 기관 분비물(organ secretions), 세포(cell), 세포 추출물(cell extract) 또는 뇌척수액(cerebrospinal fluid)을 포함하는, 정보 제공 방법.
- 제 14항에 있어서,상기 단백질 또는 이의 단편의 발현 수준의 측정 방법은 단백질 칩 분석, 면역측정법, 리간드 바인딩 어세이, MALDI-TOF(Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, SELDI-TOF(Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, 방사선 면역 분석, 방사 면역 확산법, 오우크테로니 면역 확산법, 로케트 면역전기영동, 조직면역 염색, 보체 고정 분석법, 2차원 전기영동 분석, 액상 크로마토그래피-질량분석(liquid chromatography-Mass Spectrometry, LC-MS), LC-MS/MS(liquid chromatography-Mass Spectrometry/ Mass Spectrometry), 웨스턴 블랏팅 또는 ELISA(enzyme linked immunosorbentassay)에 의해 수행되는, 정보 제공 방법.
- 제 14항에 있어서,상기 단백질 또는 이의 단편을 암호화하는 유전자의 발현 수준을 측정하는 방법은 역전사 중합효소반응(RT-PCR), 경쟁적 역전사 중합효소반응(Competitive RT-PCR), 실시간 역전사 중합효소반응(Real-time RT-PCR), RNase 보호 분석법(RPA; RNase protection assay), 노던 블랏팅(Northern blotting) 또는 DNA 칩에 의해 수행되는, 정보 제공 방법.
- 제 11항 내지 제 16항 중 어느 한 항에 있어서,상기 암은 난소암, 대장암, 췌장암, 위암, 간암, 유방암, 자궁경부암, 갑상선암, 부갑상선암, 폐암, 비소세포성폐암, 전립선암, 담낭암, 담도암, 비호지킨 림프종, 호지킨 림프종, 혈액암, 방광암, 신장암, 흑색종, 결장암, 골암, 피부암, 두부암, 자궁암, 직장암, 뇌종양, 항문부근암, 나팔관암종, 자궁내막암종, 질암, 음문암종, 식도암, 소장암, 내분비선암, 부신암, 연조직 육종, 요도암, 음경암, 수뇨관암, 신장세포 암종, 신장골반 암종, 중추신경계(CNS central nervoussystem) 종양, 1차 CNS 림프종, 척수 종양, 뇌간 신경교종 또는 뇌하수체 선종인, 정보 제공 방법.
- RGS1; F5 및 CD27로 구성된 군으로부터 선택된 어느 하나의 단백질 또는 이의 단편; 또는 이를 암호화하는 유전자의 발현 수준을 측정하는 제제를 포함하는 면역 관련 질환의 진단용 조성물.
- 제 18항에 있어서,상기 단백질은 조절 T 세포의 표면에 특이적으로 발현하는 세포표면 단백질인, 진단용 조성물.
- 제 19항에 있어서,상기 조절 T 세포는 작용 조절 T 세포, 기억 조절 T 세포, 암 침윤 림프구 조절 T 세포로 이루어진 군에서 1종 이상이 포함되는 세포표면 단백질인, 진단용 조성물.
- 제 20항에 있어서,상기 단백질 또는 이의 단편의 발현 수준을 측정하는 제제는 상기 단백질 또는 이의 단편에 특이적으로 결합하는 항체, 올리고펩타이드, 리간드, PNA(peptide nucleic acid) 및 앱타머(aptamer)로 이루어진 군에서 선택된 1종 이상을 포함하는, 진단용 조성물.
- 제 20항에 있어서,상기 단백질 또는 이의 단편을 암호화하는 유전자의 발현 수준을 측정하는 제제는 상기 유전자에 특이적으로 결합하는 프라이머, 프로브 및 안티센스 뉴클레오티드로 이루어진 군에서 선택된 1종 이상을 포함하는, 진단용 조성물.
- 제 18항 내지 22항 중 어느 한 항에 있어서,상기 면역 관련 질환은 자가면역질환; 이식편대숙주 질환; 장기이식거부반응; 천식; 아토피; 또는 급성 또는 만성의 염증 질환인, 진단용 조성물.
- 제 23항에 있어서,상기 자가면역질환은 류마티스성 관절염, 전신성 경피증, 전신 홍반성 낭창, 아토피 피부염, 건선, 원형탈모증, 천식, 크론씨병, 베체시병, 쇼그렌 증후군, 길리아-바레 증후군, 만성 갑상선염, 다발성 경화증, 다발성 근염, 강직성 척추염, 섬유조직염 및 결절성 다발성 동맥염으로 구성된 군으로부터 선택되는, 진단용 조성물.
- 제 18항 내지 제 24항 중 어느 한 항의 진단용 조성물을 포함하는 면역 관련 질환 진단용 키트.
- 목적하는 개체로부터 분리된 생물학적 시료에서 RGS1; F5 및 CD27로 구성된 군으로부터 선택된 어느 하나의 단백질 또는 이의 단편; 또는 이를 암호화하는 유전자의 발현 수준을 측정하는 단계를 포함하는 암 질환을 진단하기 위한 정보 제공 방법.
- 제 26항에 있어서,상기 단백질은 조절 T 세포의 표면에 특이적으로 발현하는 세포표면 단백질인, 정보 제공 방법.
- 제 27항에 있어서,상기 조절 T 세포는 작용 조절 T 세포, 기억 조절 T 세포, 암 침윤 림프구 조절 T 세포로 이루어진 군에서 1종 이상이 포함되는 세포표면 단백질인, 정보 제공 방법.
- 제 28항에 있어서,상기 생물학적 시료는 전혈(whole blood), 백혈구(leukocytes), 말초혈액 단핵 세포(peripheral blood mononuclear cells), 백혈구 연층(buffy coat), 혈장(plasma), 혈청(serum), 객담(sputum), 눈물(tears), 점액(mucus), 세비액(nasal washes), 비강 흡인물(nasal aspirate), 호흡(breath), 소변(urine), 정액(semen), 침(saliva), 복강 세척액(peritoneal washings), 골반 내 유체액(pelvic fluids), 낭종액(cystic fluid), 뇌척수막 액(meningeal fluid), 양수(amniotic fluid), 선액(glandular fluid), 췌장액(pancreatic fluid), 림프액(lymph fluid), 흉수(pleural fluid), 유두 흡인물(nipple aspirate), 기관지 흡인물(bronchial aspirate), 활액(synovial fluid), 관절 흡인물(joint aspirate), 기관 분비물(organ secretions), 세포(cell), 세포 추출물(cell extract) 또는 뇌척수액(cerebrospinal fluid)을 포함하는, 정보 제공 방법.
- 제 29항에 있어서,상기 단백질 또는 이의 단편의 발현 수준의 측정 방법은 단백질 칩 분석, 면역측정법, 리간드 바인딩 어세이, MALDI-TOF(Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, SELDI-TOF(Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, 방사선 면역 분석, 방사 면역 확산법, 오우크테로니 면역 확산법, 로케트 면역전기영동, 조직면역 염색, 보체 고정 분석법, 2차원 전기영동 분석, 액상 크로마토그래피-질량분석(liquid chromatography-Mass Spectrometry, LC-MS), LC-MS/MS(liquid chromatography-Mass Spectrometry/ Mass Spectrometry), 웨스턴 블랏팅 또는 ELISA(enzyme linked immunosorbentassay)에 의해 수행되는, 정보 제공 방법.
- 제 29항에 있어서,상기 단백질 또는 이의 단편을 암호화하는 유전자의 발현 수준을 측정하는 방법은 역전사 중합효소반응(RT-PCR), 경쟁적 역전사 중합효소반응(Competitive RT-PCR), 실시간 역전사 중합효소반응(Real-time RT-PCR), RNase 보호 분석법(RPA; RNase protection assay), 노던 블랏팅(Northern blotting) 또는 DNA 칩에 의해 수행되는, 정보 제공 방법.
- 제 26항 내지 제 31항 중 어느 한 항에 있어서,상기 면역 관련 질환은 자가면역질환; 이식편대숙주 질환; 장기이식거부반응; 천식; 아토피; 또는 급성 또는 만성의 염증 질환인, 정보 제공 방법.
- 제 32항에 있어서,상기 자가면역질환은 류마티스성 관절염, 전신성 경피증, 전신 홍반성 낭창, 아토피 피부염, 건선, 원형탈모증, 천식, 크론씨병, 베체시병, 쇼그렌 증후군, 길리아-바레 증후군, 만성 갑상선염, 다발성 경화증, 다발성 근염, 강직성 척추염, 섬유조직염 및 결절성 다발성 동맥염으로 구성된 군으로부터 선택되는, 정보 제공 방법.
- RGS1; F5 및 CD27로 구성된 군으로부터 선택된 어느 하나의 단백질 또는 이의 단편; 또는 이를 암호화하는 유전자의 발현 수준을 측정하는 제제를 포함하는 뇌신경계 질환의 진단용 조성물.
- 제 34항에 있어서,상기 단백질은 조절 T 세포의 표면에 특이적으로 발현하는 세포표면 단백질인, 진단용 조성물.
- 제 35항에 있어서,상기 조절 T 세포는 작용 조절 T 세포, 기억 조절 T 세포, 암 침윤 림프구 조절 T 세포로 이루어진 군에서 1종 이상이 포함되는 세포표면 단백질인, 진단용 조성물.
- 제 36항에 있어서,상기 단백질 또는 이의 단편의 발현 수준을 측정하는 제제는 상기 단백질 또는 이의 단편에 특이적으로 결합하는 항체, 올리고펩타이드, 리간드, PNA(peptide nucleic acid) 및 앱타머(aptamer)로 이루어진 군에서 선택된 1종 이상을 포함하는, 진단용 조성물.
- 제 36항에 있어서,상기 단백질 또는 이의 단편을 암호화하는 유전자의 발현 수준을 측정하는 제제는 상기 유전자에 특이적으로 결합하는 프라이머, 프로브 및 안티센스 뉴클레오티드로 이루어진 군에서 선택된 1종 이상을 포함하는, 진단용 조성물.
- 제 34항 내지 제 38항 중 어느 한 항에 있어서,상기 뇌신경계 질환은 신경 퇴행성 질환 또는 신경 염증성 질환인, 진단용 조성물.
- 제 39항에 있어서,상기 신경 퇴행성 질환 또는 신경 염증성 질환은 뇌졸중, 치매, 알츠하이머병(Alzheimer's disease), 파킨슨병(Parkinson's disease), 헌팅턴병(Huntington's disease), 니만-피크병(Niemann-Pick disease), 다발성 경화증, 프리온병(prion disease), 크로이펠츠-야콥병(Creutzfeldt-Jakob disease), 전두측두치매, 루이치매, 근위축성 측삭경화증(AlzAmyotrophic lateral sclerosis), 부신생물증후군(Paraneoplastic syndrome), 피질기저퇴행증, 다계통위축병, 진행성핵상마비, 신경계 자가면역질환, 척수 소뇌 실조(spinocerebellar ataxia), 염증성 및 신경병증성 통증, 뇌혈관 질환, 척수 손상(spinal cord injury) 및 타우병증(tauopathy)으로 이루어진 군에서 선택되는, 진단용 조성물.
- 제 34항 내지 제 40항 중 어느 한 항의 진단용 조성물을 포함하는 뇌신경계 질환 진단용 키트.
- 목적하는 개체로부터 분리된 생물학적 시료에서 RGS1; F5 및 CD27로 구성된 군으로부터 선택된 어느 하나의 단백질 또는 이의 단편; 또는 이를 암호화하는 유전자의 발현 수준을 측정하는 단계를 포함하는 뇌신경계 질환을 진단하기 위한 정보 제공 방법.
- 제 42항에 있어서,상기 단백질은 조절 T 세포의 표면에 특이적으로 발현하는 세포표면 단백질인, 정보 제공 방법.
- 제 43항에 있어서,상기 조절 T 세포는 작용 조절 T 세포, 기억 조절 T 세포, 암 침윤 림프구 조절 T 세포로 이루어진 군에서 1종 이상이 포함되는 세포표면 단백질인, 정보 제공 방법.
- 제 44항에 있어서,상기 생물학적 시료는 전혈(whole blood), 백혈구(leukocytes), 말초혈액 단핵 세포(peripheral blood mononuclear cells), 백혈구 연층(buffy coat), 혈장(plasma), 혈청(serum), 객담(sputum), 눈물(tears), 점액(mucus), 세비액(nasal washes), 비강 흡인물(nasal aspirate), 호흡(breath), 소변(urine), 정액(semen), 침(saliva), 복강 세척액(peritoneal washings), 골반 내 유체액(pelvic fluids), 낭종액(cystic fluid), 뇌척수막 액(meningeal fluid), 양수(amniotic fluid), 선액(glandular fluid), 췌장액(pancreatic fluid), 림프액(lymph fluid), 흉수(pleural fluid), 유두 흡인물(nipple aspirate), 기관지 흡인물(bronchial aspirate), 활액(synovial fluid), 관절 흡인물(joint aspirate), 기관 분비물(organ secretions), 세포(cell), 세포 추출물(cell extract) 또는 뇌척수액(cerebrospinal fluid)을 포함하는, 정보 제공 방법.
- 제 45항에 있어서,상기 단백질 또는 이의 단편의 발현 수준의 측정 방법은 단백질 칩 분석, 면역측정법, 리간드 바인딩 어세이, MALDI-TOF(Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, SELDI-TOF(Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, 방사선 면역 분석, 방사 면역 확산법, 오우크테로니 면역 확산법, 로케트 면역전기영동, 조직면역 염색, 보체 고정 분석법, 2차원 전기영동 분석, 액상 크로마토그래피-질량분석(liquid chromatography-Mass Spectrometry, LC-MS), LC-MS/MS(liquid chromatography-Mass Spectrometry/ Mass Spectrometry), 웨스턴 블랏팅 또는 ELISA(enzyme linked immunosorbentassay)에 의해 수행되는, 정보 제공 방법.
- 제 45항에 있어서,상기 단백질 또는 이의 단편을 암호화하는 유전자의 발현 수준을 측정하는 방법은 역전사 중합효소반응(RT-PCR), 경쟁적 역전사 중합효소반응(Competitive RT-PCR), 실시간 역전사 중합효소반응(Real-time RT-PCR), RNase 보호 분석법(RPA; RNase protection assay), 노던 블랏팅(Northern blotting) 또는 DNA 칩에 의해 수행되는, 정보 제공 방법.
- 제 42항 내지 제 47항 중 어느 한 항에 있어서,상기 뇌신경계 질환은 신경 퇴행성 질환 또는 신경 염증성 질환인, 정보 제공 방법.
- 제 48항에 있어서,상기 신경 퇴행성 질환 또는 신경 염증성 질환은 뇌졸중, 치매, 알츠하이머병(Alzheimer's disease), 파킨슨병(Parkinson's disease), 헌팅턴병(Huntington's disease), 니만-피크병(Niemann-Pick disease), 다발성 경화증, 프리온병(prion disease), 크로이펠츠-야콥병(Creutzfeldt-Jakob disease), 전두측두치매, 루이치매, 근위축성 측삭경화증(AlzAmyotrophic lateral sclerosis), 부신생물증후군(Paraneoplastic syndrome), 피질기저퇴행증, 다계통위축병, 진행성핵상마비, 신경계 자가면역질환, 척수 소뇌 실조(spinocerebellar ataxia), 염증성 및 신경병증성 통증, 뇌혈관 질환, 척수 손상(spinal cord injury) 및 타우병증(tauopathy)으로 이루어진 군에서 선택되는, 정보 제공 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22892259.7A EP4431944A1 (en) | 2021-11-12 | 2022-11-14 | Biomarker for regulatory t cell |
KR1020247019379A KR20240099472A (ko) | 2021-11-12 | 2022-11-14 | 조절 t세포의 바이오 마커 |
CN202280075543.2A CN118339455A (zh) | 2021-11-12 | 2022-11-14 | 调节性t细胞的生物标志物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163278610P | 2021-11-12 | 2021-11-12 | |
US63/278,610 | 2021-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023084474A1 true WO2023084474A1 (ko) | 2023-05-19 |
Family
ID=86335202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/060908 WO2023084474A1 (ko) | 2021-11-12 | 2022-11-14 | 조절 t세포의 바이오 마커 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4431944A1 (ko) |
KR (1) | KR20240099472A (ko) |
CN (1) | CN118339455A (ko) |
WO (1) | WO2023084474A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140061374A (ko) * | 2011-07-01 | 2014-05-21 | 베크만 컬터, 인코포레이티드 | 조절 t 세포, 및 cd6-발현 또는 cd4, cd25 및 cd127의 조합을 사용하여 이를 확인 및 단리하는 방법 |
KR20210004888A (ko) * | 2019-07-04 | 2021-01-13 | 주식회사 굳티셀 | T 세포의 세포 표면 항원 및 이의 다양한 용도 |
WO2021165546A1 (en) * | 2020-02-20 | 2021-08-26 | Institut Curie | Method for identifying functional disease-specific regulatory t cells |
-
2022
- 2022-11-14 EP EP22892259.7A patent/EP4431944A1/en active Pending
- 2022-11-14 CN CN202280075543.2A patent/CN118339455A/zh active Pending
- 2022-11-14 WO PCT/IB2022/060908 patent/WO2023084474A1/ko active Application Filing
- 2022-11-14 KR KR1020247019379A patent/KR20240099472A/ko unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140061374A (ko) * | 2011-07-01 | 2014-05-21 | 베크만 컬터, 인코포레이티드 | 조절 t 세포, 및 cd6-발현 또는 cd4, cd25 및 cd127의 조합을 사용하여 이를 확인 및 단리하는 방법 |
KR20210004888A (ko) * | 2019-07-04 | 2021-01-13 | 주식회사 굳티셀 | T 세포의 세포 표면 항원 및 이의 다양한 용도 |
WO2021165546A1 (en) * | 2020-02-20 | 2021-08-26 | Institut Curie | Method for identifying functional disease-specific regulatory t cells |
Non-Patent Citations (11)
Title |
---|
BOCK L C ET AL., NATURE, vol. 355, no. 6360, 1992, pages 5646 |
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
COHEN B ACOLAS PBRENT R: "An artificial cell-cycle inhibitor isolated from a combinatorial library", PROC NATL ACAD SCI USA., vol. 95, no. 24, 1998, pages 142727 |
DUGGLEBY RICHARD C ET AL: "CD27 expression discriminates between regulatory and non-regulatory cells after expansion of human peripheral blood CD4+ CD25+ cells.", CANCER RESEARCH, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 121, no. 1, 1 May 2007 (2007-05-01), GB , pages 129 - 139, XP002457228, ISSN: 0019-2805, DOI: 10.1111/j.1365-2567.2006.02550.x * |
HOPPE-SEYLER FBUTZ K: "Peptide aptamers: powerful new tools for molecular medicine", J MOL MED., vol. 78, no. 8, 2000, pages 42630, XP002413234, DOI: 10.1007/s001090000140 |
KOHLERMILSTEIN, EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 6, 1976, pages 511 - 519 |
LI SHILONG, YANG HUAXIANG, LI SHULIANG, ZHAO ZONGXIAN, WANG DAOHAN, FU WEIHUA: "High expression of regulator of G‑protein signalling 1 is associated with the poor differentiation and prognosis of gastric cancer", ONCOLOGY LETTERS, SPANDIDOS PUBLICATIONS, GR, vol. 21, no. 4, GR , XP093066653, ISSN: 1792-1074, DOI: 10.3892/ol.2021.12584 * |
MARK, MOLECULAR THERAPY, vol. 13, 2006, pages 644 - 670 |
MARKS ET AL., J. MOL. BIOL., vol. 222, no. 58, 1991, pages 1 - 597 |
NAT PROTOC, vol. 9, no. 1, January 2014 (2014-01-01), pages 171 - 81 |
NIELSEN P EEGHOLM MBERG R HBUCHARDT O: "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide", SCIENCE, vol. 254, no. 5037, December 1991 (1991-12-01), pages 1497 - 1500, XP002912953, DOI: 10.1126/science.1962210 |
Also Published As
Publication number | Publication date |
---|---|
EP4431944A1 (en) | 2024-09-18 |
CN118339455A (zh) | 2024-07-12 |
KR20240099472A (ko) | 2024-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gallarda et al. | The beta-globin stage selector element factor is erythroid-specific promoter/enhancer binding protein NF-E4. | |
WO2018097951A1 (en) | Anti-mage-a3/a6 antibodies | |
WO2017010744A1 (ko) | 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법 | |
US8604173B2 (en) | Dopaminergic neuron progenitor cell marker 187A5 | |
JP4926966B2 (ja) | ドーパミン産生ニューロン増殖前駆細胞マーカーMsx1/2 | |
WO2021177691A1 (ko) | 항암제 내성 진단 또는 치료용 조성물 | |
WO2021172890A1 (ko) | Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도 | |
WO2010036031A2 (en) | Pauf-specific human monoclonal antibody, pharmaceutical composition for treating cancer comprising the same and method for detecting cancer using the same | |
WO2023084474A1 (ko) | 조절 t세포의 바이오 마커 | |
CN110256562B (zh) | Pd-1纳米抗体、制备方法及其应用 | |
WO2022131889A1 (ko) | Taci 단백질의 용도 | |
WO2022086197A1 (ko) | 활성화된 면역 세포의 세포 표면 항원 및 이의 다양한 용도 | |
CN114656561B (zh) | 一种抗ip-10单克隆抗体 | |
KR101309485B1 (ko) | 비브리오 패혈증균 알티엑스에이원에 특이적인 단일클론항체, 이를 분비하는 하이브리도마 및 이를 포함하는 진단키트 | |
WO2016209013A1 (ko) | 비만 진단용 마커 tm4sf19 및 이를 이용한 방법 | |
WO2024151091A1 (ko) | 종양 내 treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물 | |
WO2024144287A1 (ko) | 알파시누클레인에 의한 혈액-뇌장벽 손상 진단용 마커 및 이의 용도 | |
WO2016200246A1 (ko) | 담도암의 항암제 내성 진단용 신규 바이오마커 및 이의 용도 | |
WO2022121899A1 (zh) | 一种特异性结合Strep-Tag II标签的抗体及其应用 | |
WO2022055093A1 (ko) | 종양미세환경 회피능을 갖는 면역세포치료제 조성물 | |
WO2023177246A1 (ko) | Egfrviii 특이적 압타머 및 이의 용도 | |
EP4032914A1 (en) | Antibody for detecting acetylation of cox2 protein, and uses thereof | |
WO2022092643A1 (ko) | Wars 및 사이토카인 농도에 기초한 감염성 염증 질환에 대한 사망 위험도 판별방법 | |
WO2022124764A1 (ko) | Cd47에 특이적인 항체 및 이의 용도 | |
WO2023042944A1 (ko) | 위암의 예방, 개선 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22892259 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280075543.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020247019379 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022892259 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022892259 Country of ref document: EP Effective date: 20240612 |